CFB has received grant/research support from Elan Pharmaceutical, NARSAD; consultant for AstraZeneca; and serves on the speakers bureau for AstraZeneca, GlaxoSmithKline, Eli Lilly & Co. SNG has received grant/research support from Elan Pharmaceutical, Janssen; consultant for Janssen; and serves on the speakers bureau for GlaxoSmithKline, Eli Lilly & Co., Janssen. ML, AC and AL have no reported conflict of interest.
Acute treatment of bipolar depression with adjunctive zonisamide: a retrospective chart review
Article first published online: 21 SEP 2004
Volume 6, Issue 5, pages 432–434, October 2004
How to Cite
Baldassano, C. F., Nassir Ghaemi, S., Chang, A., Lyman, A. and Lipari, M. (2004), Acute treatment of bipolar depression with adjunctive zonisamide: a retrospective chart review. Bipolar Disorders, 6: 432–434. doi: 10.1111/j.1399-5618.2004.00143.x
- Issue published online: 21 SEP 2004
- Article first published online: 21 SEP 2004
- Received 14 November 2003, revised and accepted for publication 21 June 2004
- bipolar disorder;
Background: This retrospective chart review evaluated the use of zonisamide as adjunctive treatment in patients with bipolar depression.
Method: The charts of outpatients with bipolar I or II disorder treated with adjunctive zonisamide were reviewed. The efficacy of zonisamide was assessed via comparison of physician-rated Global Assessment of Functioning (GAF) and Clinical Global Impression of Severity (CGI-S) Scale scores at baseline and after 6 weeks of therapy using paired t-tests. Patients who scored ≤2 on the CGI-S after 6 weeks of zonisamide therapy were considered good responders to zonisamide.
Results: Charts for 12 patients (four men and eight women) with a mean (±SD) age of 39.6 (±7.6) years were evaluated. Patients received a mean (±SD) zonisamide dosage of 236 (±68) mg/day. Mean GAF scores significantly improved from 44.0 at baseline to 59.3 at week 6 (P = 0.05). Mean CGI-S scores improved from 4.54 at baseline to 3.42 at week 6, but the change was not statistically significant. Six patients (50.0%) were considered responders to zonisamide. Four patients discontinued zonisamide therapy, two for an adverse event (sedation) and two for lack of efficacy.
Conclusions: Zonisamide may be a useful adjunctive treatment for some patients with bipolar depression. Conclusions from this study are limited due to its retrospective design. Further investigation of zonisamide in the treatment of bipolar depression is warranted.